Addendum
Dolutegravir (HIV infection) - Addendum to commission A17-11
Report documents
-
Addendum
Dolutegravir (HIV infection) - Addendum to commission A17-11
Dossier assessment
Indication:
HIV infection in children with antiretroviral pretreatment or in treatment-naive children
Result of dossier assessment:
Added benefit still not proven: data from studies in adults not transferable to children
Additional information
Federal Joint Committee (G-BA)
2017-09-21 A G-BA decision was published.
Project details
- Project no.
- A17-37
- Commission
- Commission awarded on 10.08.2017 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Immune system and infections
- Note
-
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Connected Projects
-
Dossier assessment
Dolutegravir (HIV infection) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed